|1.||Efferth, Thomas: 2 articles (08/2010 - 08/2003)|
|2.||Elliott, Gary: 2 articles (02/2006 - 04/2004)|
|3.||Chen, Li-Tzong: 1 article (11/2014)|
|4.||Kung, Hsing-Jien: 1 article (11/2014)|
|5.||Yu, Shih Chen: 1 article (11/2014)|
|6.||Li, Shau-Hsuan: 1 article (11/2014)|
|7.||Fang, Fu-Min: 1 article (11/2014)|
|8.||Wang, Yu-Hui: 1 article (11/2014)|
|9.||Tsai, Jen-Wei: 1 article (11/2014)|
|10.||Huang, Hsuan-Ying: 1 article (11/2014)|
|1.||Hepatocellular Carcinoma (Hepatoma)
02/01/2009 - "This phase II study was designed to evaluate the efficacy and safety of L-alanosine in patients with MTAP-deficient solid tumors. "
04/25/2004 - "The method was validated and applied for clinical studies of alanosine administered to cancer patients."
01/01/2004 - "An in vivo study using HT-1080 cell tumors with and without MTAP expression confirmed that tumors lacking MTAP were more sensitive to L-alanosine than tumors expressing MTAP. "
11/01/2001 - "Researchers at UCSD found that some types of cancer lack MTAP, which was responsible for alanosine's previous clinical failure ; phase II trials were being carried out at the university in 1997 . "
05/01/1981 - "Studies on the mechanism of resistance of selected murine tumors to L-alanosine."
|3.||Melanoma (Melanoma, Malignant)
10/01/1984 - "L-alanosine as used in our study has limited activity against malignant melanoma."
10/01/1984 - "Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma."
10/01/1984 - "The authors conducted a phase II study of L-alanosine in 39 patients (19 without prior chemotherapy) in advanced malignant melanoma. "
07/01/1987 - "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma. "
07/01/1987 - "Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma."
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
02/01/2006 - "EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine."
04/01/1999 - "Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro."
11/01/2001 - "As of May 2001, UCSD's ongoing clinical trials of alanosine included phase II trials for non-small cell lung cancer (NSCLC) and phase I trials for acute lymphoid leukemia (ALL), while a phase II trial for glioma at UCSD had been suspended . "
02/01/2006 - "The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthesis. "
|5.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
04/01/1999 - "Thus, our results support the use of L-alanosine alone or in combination with a salvage agent as a MTAP-selective therapy and therefore lay the foundation for the initiation of clinical trials for the treatment of T-ALL and other MTAP-deficient malignancies with L-alanosine."
02/01/2006 - "EFA at 20 microM or less rescued primary MTAP+ T-ALL cells and normal lymphocytes from L-alanosine toxicity. "
02/01/2006 - "We demonstrate that MTAP- T-ALL cells obtained at relapse are as sensitive to L-alanosine toxicity as diagnosis samples. "
04/01/1999 - "Furthermore, normal lymphocytes and MTAP+ primary T-ALL cells were rescued from L-alanosine toxicity by the MTAP substrate 5'-deoxyadenosine, but MTAP-T-ALL cells were not. "
04/01/1999 - "We now report that MTAP-primary T-ALL cells are more sensitive to the toxicity of L-alanosine, an inhibitor of de novo AMP synthesis, than are MTAP+ primary T-ALL cells. "
|1.||Aspartic Acid (Aspartate)
|4.||alanosine (SDX 102)
|5.||NSC 224131 (PALA)
|6.||Adenosine Monophosphate (AMP)
|7.||5'-methylthioadenosine phosphorylase (methylthioadenosine nucleosidase)
|8.||Vinblastine (Vinblastine Sulfate)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)